DUBLIN – Immatics Biotechnologies GmbH is banking $50 million up front and could earn up to $550 million more in per-product milestones from an adoptive cell therapy deal in solid tumor indications with Glaxosmithkline plc, which initially involves two autologous cell therapies engineered to express T-cell receptors (TCRs) that bind novel cancer targets. Immatics would receive royalties on sales of any approved therapies. Read More
Teva Pharmaceutical Industries Ltd.’s Austedo (deutetrabenazine) lived up to the lack of expectations in pediatric Tourette syndrome (TS), missing identical primary endpoints in a pair of late-stage trials. Read More
With deeming day a little more than a month away, the FDA is taking final steps to ease the transition of simple proteins approved as new drug applications (NDAs) to biologic license applications (BLAs). The March 23 change will open drugs such as insulin and various hormones to new competition, likely bringing in the next wave of biosimilars. And this time, interchangeability could be riding the crest. Read More
Beyond every binary is a more complex reality. And so it is with driver and passenger mutations. The separation of tumor mutations into drivers and passengers underpins much progress in the development of targeted therapies. By looking at passenger mutations more carefully, though, researchers at Yale University have shown that passenger mutations, too, played a role in how tumors progressed. Read More
HYDERABAD, India – Multinationals and domestic companies are stepping up research in India, including working to leverage the country’s digital and entrepreneurial capabilities, to boost India’s capabilities and market share in more innovative biologic drugs. Read More
Infectious disease has been rough going for all comers the past few years, as companies have floundered. Appili Therapeutics Inc.’s CEO, Armand Balboni saw the troubles others encountered with the indication and also saw companies with thin pipelines struggle, but it hasn’t stopped him from forging on. Read More
PERTH, Australia – Medicinal cannabis company Zelira Therapeutics Ltd. reported that its ZLT-101 therapy met the primary endpoint of a statistically significant improvement in insomnia in a phase Ib/IIa study in patients diagnosed with chronic insomnia. Read More
Nantomics LLC, of Culver City, Calif., reported that research based on the company’s deep learning system has been published in a peer-reviewed journal, highlighting the algorithm’s ability to discern which mutation drives a patient’s breast cancer. Read More
Biopharmas raising money in public or private financings, including: Aeterna Zentaris, Alladapt, Axovant, Bioxcel, Deciphera, Hemostemix, Spruce. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adial, Forma, Heron
. Read More
